Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Indivior plc
Oncology drug sales plummeted during the pandemic leading to a backlog of untreated patients that lingered even after the impact of COVID-19 drugs. While Q2 reports suggest this cancer backlog is now being addressed, the contrasting fates of vaccines and treatments for SARS-CoV-2 are actually turning out to be opaquer than expected.
Company to pay $900m to resolve claims it paid kickbacks to physicians to induce them to prescribe its multiple sclerosis drugs. Whistleblower sought damages based on the number of prescriptions written after a healthcare provider received a kickback from Biogen.
Training talent from other highly regulated industries, apprenticeships and targeting primary schools are key to addressing the skills shortage in the advanced therapies space.
The potential for RNA medicines to achieve holy grail goals – reaching undruggable targets and bringing drugs to market faster – has Pfizer, Lilly, Novartis and others in a deal-making frame of mind.
- Drug Delivery
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Indivior Inc.
- Indivior UK Limited
- Reckitt Benckiser Pharmaceuticals Inc. (RBP)